Aside from being founder and CEO of Vanguard Clinical, Tiffany Sepp is a rare-disease advocate reshaping how clinical trials are designed, led, and delivered. With an early academic foundation in Biology and English Literature from UC San Diego, Tiffany built her career at the intersection of science, storytelling, and human urgency—an uncommon blend that now defines her leadership across both the biotech and rare-disease communities.

Under her leadership, Vanguard has grown into a boutique, “white-glove” CRO known for rescuing complex programs, delivering operational clarity, and serving as a true extension of sponsor teams. Tiffany remains hands-on in the work—diving into clinical operations oversight, shaping strategy, and cultivating strong sponsor, site, and vendor partnerships that accelerate execution.